Zincke H, Woods J E, Holley K E
Urology. 1977 Oct;10(4):301-4. doi: 10.1016/0090-4295(77)90154-6.
The intravenous administration of high doses of methylprednisolone and cyclophosphamide during pretreatment of the heart-beating canine and human cadaveric allograft donor has caused no observable adverse effect on renal allografts. This is in contrast to that noted when high doses of these drugs are added to the preservation perfusate in which they are not metabolized and may possibly cause renal damage.